| Code | CSB-RA624104MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Turenkibart, designed for research applications targeting interleukin-17A (IL-17A). IL-17A is a pro-inflammatory cytokine primarily produced by Th17 cells that plays a central role in host defense against extracellular pathogens and in the pathogenesis of various autoimmune and inflammatory conditions. This cytokine promotes neutrophil recruitment, induces the production of antimicrobial peptides, and stimulates the release of additional inflammatory mediators. Dysregulated IL-17A signaling has been implicated in psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease.
Turenkibart is a therapeutic monoclonal antibody that selectively binds and neutralizes IL-17A, preventing its interaction with IL-17 receptors. As a research-grade biosimilar, this antibody provides investigators with a valuable tool for studying IL-17A biology, exploring inflammatory disease mechanisms, and evaluating potential therapeutic interventions in preclinical models. It enables researchers to investigate the specific contributions of IL-17A in immune responses and disease pathology across various experimental systems.
There are currently no reviews for this product.